Welcome to our dedicated page for QUALYS SEC filings (Ticker: QLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Qualys, Inc. filings document the regulatory disclosures of a Delaware software company providing cloud-based IT, security and compliance solutions. Its 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP operating measures, guidance and conference-call materials.
Proxy materials cover annual meeting mechanics, Class II director elections, auditor ratification, advisory executive compensation votes and amendments to the 2012 Equity Incentive Plan. The filings also reflect public-company governance, common-stock voting matters and compensation-plan disclosures.
John A. Zangardi, a director of Qualys, Inc. (QLYS), reported the sale of 3,860 shares of the issuer's common stock on 08/22/2025. The filing shows the sale code "S" with a weighted average sale price of $134.8197, and an indicated price range of $134.575 to $135.12 per share. After the reported transaction the filing lists 7,174 shares beneficially owned directly and an indirect holding of 5 shares attributed to his son. The Form 4 was signed by Bruce Posey by power of attorney on 08/25/2025. This report is a Section 16 disclosure of insider selling and provides the weighted average price range for the shares sold.
Form 4 shows that Kristi Marie Rogers, a director of Qualys, Inc. (QLYS), sold 1,700 shares of the company's common stock on 08/22/2025 at a reported price of $134.7047 per share. After this sale she beneficially owned 8,596 shares, held directly. The filing was signed on 08/25/2025 by Bruce Posey as attorney-in-fact.
Qualys, Inc. (QLYS) Form 144 filed to report a proposed sale of 1,700 shares of common stock through Morgan Stanley Smith Barney LLC on 08/22/2025. The filing shows the shares were acquired on 06/07/2024 as restricted stock that vested under a registered plan and the acquisition was part of compensation. The aggregate market value of the proposed sale is listed as $229,313.00 and the company had 36,095,879 shares outstanding per the form. The filer indicates there were no other sales by the reporting person in the prior three months and provides the standard signature representation regarding material nonpublic information.
Bruce K. Posey, Chief Legal Officer of Qualys, Inc. (QLYS), reported sales of common stock on 08/20/2025 executed under a Rule 10b5-1 trading plan adopted on 08/21/2024. The Form 4 discloses three sale entries: 308 shares at a weighted average price of $131.8922, 192 shares at $132.7383, and 25 shares at $133.618, leaving the reporting person with 57,840 shares beneficially owned after the transactions.
The filing indicates the sales were planned pursuant to the pre-established 10b5-1 plan and provides price ranges for the component trades. The reporting person signed the Form 4 on 08/21/2025. All information above is taken directly from the filed Form 4.
Qualys, Inc. (QLYS) Form 144 notice for proposed sale of securities. The filing shows an intended sale of 3,860 common shares through Charles Schwab with an aggregate market value of $503,652.00 and an approximate sale date of 08/21/2025 on Nasdaq. The shares were acquired as vested restricted stock grants from the issuer on 06/12/2020 and were issued as equity compensation. The filing also discloses a prior sale by the same person, John A. Zangardi, of 1,287 shares on 08/13/2025 for gross proceeds of $169,918.23. Certain identifying fields such as filer CIK/CCC and explicit relationship to the issuer are not provided in the text.
Qualys, Inc. insider notice reports a proposed sale of 1,590 common shares (restricted stock units) through Morgan Stanley Smith Barney, with an aggregate market value of $211,629.00. The securities were acquired as RSUs on 08/01/2025 and the planned approximate sale date is 08/20/2025 on NASDAQ. The filer also recorded two recent 10b5-1 sales by Bruce K. Posey: 541 shares on 07/21/2025 for $75,800.02 and 525 shares on 06/20/2025 for $71,379.78. Total shares outstanding noted: 36,095,879.
Wendy Pfeiffer, a director of Qualys, Inc. (QLYS), sold 200 shares of company common stock on 08/15/2025 at $129.72 per share. The Form 4 reports that after the sale she beneficially owned 11,082 shares, held directly. The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 21, 2025. The Form 4 was submitted on 08/18/2025 and signed under power of attorney by Bruce Posey.
Qualys insider transactions by CEO Sumedh S. Thakar: The filing shows the CEO exercised 6,500 stock options with a $25.56 exercise price and immediately acquired 6,500 shares. On the same date, under a Rule 10b5-1 trading plan adopted February 26, 2025, he sold 5,722 shares at a weighted average price of $129.6697 and sold 2,778 shares at a weighted average price of $130.5372, for total shares sold of 8,500. Beneficial ownership reported moved from 216,420 shares following the option acquisition to 207,920 after the sales. The option granted is fully vested and exercisable and the sales were executed pursuant to the disclosed 10b5-1 plan.
Qualys insider sale reported on Form 4. Director John A. Zangardi sold 1,287 shares of Qualys, Inc. common stock on 08/13/2025 at a reported price of $132.0266 per share. After the sale he beneficially owned 11,034 shares directly and 5 shares indirectly through his son. The form was signed by Bruce Posey by power of attorney on 08/15/2025.
Qualys, Inc. (QLYS) submitted a Form 144 indicating a proposed sale of 1,287 common shares through Charles Schwab on Nasdaq, with an aggregate market value reported as $169,951 and total shares outstanding of 36,095,879. The securities were acquired as vested restricted stock grants on 06/12/2020 and the filing lists a payment classification of equity compensation dated 06/12/2024. The sale is scheduled approximately for 08/13/2025.
This quantity represents about 0.0036% of the outstanding shares, indicating the proposed sale is immaterial to overall share capital. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information.